<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295826</url>
  </required_header>
  <id_info>
    <org_study_id>DATAS002</org_study_id>
    <nct_id>NCT02295826</nct_id>
  </id_info>
  <brief_title>Dabigatran Following Transient Ischemic Attack and Minor Stroke</brief_title>
  <acronym>DATAS II</acronym>
  <official_title>Dabigatran Following Transient Ischemic Attack and Minor Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess&#xD;
      hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown&#xD;
      to be associated with much lower intracranial hemorrhage rates. It has been suggested that&#xD;
      this agent may provide the superior benefits of anticoagulation in acute stroke, without the&#xD;
      concomitant increase in hemorrhage risk associated with heparin/LMWH or warfarin.&#xD;
&#xD;
      Study Design: DATAS II is a randomized, open label blinded endpoint trial. Participants&#xD;
      (n=300) with TIA or ischemic stroke (NIHSS score &lt;9) will be enrolled within 48 hours of&#xD;
      symptom onset from approximately four (4) health care centres across Canada. All participants&#xD;
      will have an MRI with DWI lesion volume &lt; 25 ml. Participants will be randomized 1:1 to&#xD;
      treatment with dabigatran for 30 days or ASA 81 mg daily (current standard of care). All&#xD;
      stroke patients will initially be screened with a non-contrast CT scan of the brain. The&#xD;
      first MRI will be performed within 48 hours of symptom onset. Imaging studies will be&#xD;
      repeated at day 30. All patients will be assessed clinically at Day 30 and Day 90.&#xD;
&#xD;
      Study Aims:&#xD;
&#xD;
        1. Establish the safety of early anticoagulation with the novel oral anticoagulant&#xD;
           dabigatran in acute cerebrovascular syndrome patients.&#xD;
&#xD;
        2. Identify the rate of both symptomatic and asymptomatic hemorrhagic transformation (HT)&#xD;
           associated with these treatments.&#xD;
&#xD;
        3. Identify predictors of HT associated with acute dabigatran treatment.&#xD;
&#xD;
      Hypothesis: The Investigators hypothesize that symptomatic HT rates in dabigatran and ASA&#xD;
      treated patients will not be significantly different.&#xD;
&#xD;
      Study outcomes: The primary outcome is the rate of symptomatic hemorrhagic transformation&#xD;
      (HT), defined as a parenchymal hematoma, which is &gt;30% of the infarcted area on DWI, with&#xD;
      substantial space- occupying effect, associated with clinical worsening (≥4 point increase in&#xD;
      National Institutes of Health Stroke Scale (NIHSS) score) within 5 weeks of treatment&#xD;
      initiation. The major secondary outcome the rate of asymtomatic HT see on day 30 MRI&#xD;
      sequence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of symptomatic hemorrhagic transformation</measure>
    <time_frame>within 5 weeks of treatment initiation</time_frame>
    <description>The primary endpoint is the rate of symptomatic hemorrhagic transformation (HT), defined as a parenchymal hematoma, which is &gt;30% of the infarcted area on DWI, with substantial space-occupying effect, associated with clinical worsening (≥4 point increase in National Institutes of Health Stroke Scale (NIHSS) score) within 5 weeks of treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of asymtomatic hemorrhagic transformation</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Transient Ischemic Attack</condition>
  <condition>Minor Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Dabigatran therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients &gt;80 years of age and/or an eGFR of 30-50 ml/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic Acid thereapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>325 mg loading dose then 81 mg/day for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.</description>
    <arm_group_label>Dabigatran therapy</arm_group_label>
    <other_name>Pradax (Canada)/ Pradaxa (USA and rest of world)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day</description>
    <arm_group_label>Acetylsalicylic Acid thereapy</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients&#xD;
&#xD;
          2. Must be &gt;18 years of age&#xD;
&#xD;
          3. Must have TIA or ischemic stroke (NIHSS score &lt;9 - see section 2.7 for further&#xD;
             clarification)&#xD;
&#xD;
          4. Symptom onset is &lt; 72 hours prior to enrollment or Study therapy must initiated within&#xD;
             48 hours of symptom onset (in case where onset time cannot be established, it will be&#xD;
             considered to be the time when the patient was lst know to be well&#xD;
&#xD;
          5. Informed consent must be obtained from either the patient or substitute decision maker&#xD;
             (according to local REB policy) prior to any study related procedures being performed&#xD;
&#xD;
          6. All patients will have a MRI including DWI prior to randomization&#xD;
&#xD;
          7. DWI lesion volume must be &lt;25ml&#xD;
&#xD;
          8. Patients without DWI lesions, but a clinical history considered consistent with TIA,&#xD;
             determined by the attending physician, can be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with stroke mimics - such as seizures, migraine etc&#xD;
&#xD;
          2. Patients with contraindications to MRI including metallic implants&#xD;
&#xD;
          3. Patients with any past sensitivity to gadolinium contrast media will be eligible, but&#xD;
             will not undergo PWI or contrast enhanced MRA (both optional sequences)&#xD;
&#xD;
          4. Patients with renal failure defined as Glomerular Filtration Rate (GFR) &lt; 30 ml/min&#xD;
&#xD;
          5. Patients deemed, as attending stroke physician, to have any ongoing bleeding risks or&#xD;
             unsuitable for dabigatran therapy&#xD;
&#xD;
          6. Patients with MRI demonstrated additional pathology including arteriovenous&#xD;
             malformations, intracranial aneurysms, tumors or abscess, which potentially increase&#xD;
             the rise of bleed. Individuals with small incidental leasions, at low risk of bleed&#xD;
             such as meningiomas may be included at the discretion of the investigator.&#xD;
&#xD;
          7. Patients with an acute DWI lesion volume of &gt;25 ml (DWI volume to be estimated using&#xD;
             the ABC/2 technique 110)**&#xD;
&#xD;
          8. Age &lt;18 years&#xD;
&#xD;
          9. Pregnant or breast feeding women.&#xD;
&#xD;
         10. Severe dysphagia necessitating naso-gastric (NG) feeding (dabigatran can not be&#xD;
             delivered via NG tube)&#xD;
&#xD;
         11. Planned thrombolysis or endovascular intervention for the index event&#xD;
&#xD;
         12. Thrombolysis for ischemic stroke within the preceding 7 days&#xD;
&#xD;
         13. Planned carotid endarterectomy/carotid artery stent within 30 days Note: Carotid&#xD;
             Investigations will be completed prior to enrolment. Patients with symptomatic&#xD;
             stenoses and a planned carotid procedure will be excluded.&#xD;
&#xD;
         14. Any history of spontaneous intracranial bleeding&#xD;
&#xD;
         15. Clear indication for anticoagulation, including atrial fibrillation, mechanical&#xD;
             cardiac valves, deep venous thrombosis, pulmonary embolism or known hypercoagulable&#xD;
             state&#xD;
&#xD;
         16. Co-morbid illness with expected life expectancy of &lt;90 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Stroke Program</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

